precision medicine

Quiz

Friday Morning Quiz ‚Äì Week of July 18-24

07/21/2016

JCP Editors

Updates to National Comprehensive Cancer Network guidelines released earlier this week suggested that which of the following treatments be added to standard care for mesothelioma? A. pemetrexed B. cisplatin C....

...

07/21/2016

Journal of Clinical Pathways

Research in Review

Anthracycline-based Regimens Improve Survival in Elderly Patients With Lymphoma

07/13/2016

JCP Editors

Findings from a single-center analysis have shown that anthracycline-based therapies may produce better outcomes in patients age 80 years and older with diffuse large B-cell lymphoma (DLBCL), supporting data reported...

...

07/13/2016

Journal of Clinical Pathways

Research in Review

Inherited Genes Highly Prevalent in Metastatic Prostate Cancer

07/12/2016

JCP Editors

Findings from a study recently published in the New England Journal of Medicine suggest that men with advanced prostate cancer may want to consider being tested for inherited gene mutations in order to help guide...

...

07/12/2016

Journal of Clinical Pathways

Research in Review

Neoadjuvant Endocrine Therapy for Breast Cancer Produces Same Results as Combination Chemotherapy

07/08/2016

JCP Editors

Neoadjuvant endocrine therapy (NET) may be associated with similar response rates as neoadjuvant combination chemotherapy, but with significantly lower toxicity, findings from a study published in JAMA Oncology...

...

07/08/2016

Journal of Clinical Pathways

Research in Review

NACT Spurs Immune Response in Patients With Ovarian Cancer

07/08/2016

JCP Editors

Administering immunotherapy immediately after chemotherapy may improve response when treating patients with stage IIIC-IV tubo-ovarian high-grade serous carcinoma, according to findings from a study published in...

...

07/08/2016

Journal of Clinical Pathways

Research in Review

Two Studies Support Immunotherapeutic Agent As First-Line Treatment for NSCLC

07/07/2016

JCP Editors

Nivolumab has demonstrated encouraging activity and acceptable tolerability as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC), according to the results of two phase I,...

...

07/07/2016

Journal of Clinical Pathways

Research in Review

Genetic Testing for DCIS Unnecessary, Costing the US Millions

07/05/2016

JCP Editors

Automatically testing all core needle biopsy specimens showing ductal carcinoma in situ (DCIS) for estrogen receptor (ER) and progesterone receptor (PR) is highly expensive and may not be needed, according to a study...

...

07/05/2016

Journal of Clinical Pathways

Research in Review

HOX Expression an Indicator of Survival in Patients With Ovarian Cancer

07/01/2016

JCP Editors

A study out of the United Kingdom has identified a key gene signature in ovarian cancer that may be useful in predicting survival. The HOX gene family is largely responsible for the rapid cell division seen in...

A...

07/01/2016

Journal of Clinical Pathways

Blood Test Predicts Treatment Response for NETs

06/27/2016

JCP Editors

A study presented at the 2016 Society of Nuclear Medicine and Molecular Imaging Annual Meeting (June 11-15; San Diego, CA [SNMMI]) has found that a novel investigative blood test could predict how patients with...

A...

06/27/2016

Journal of Clinical Pathways

Research in Review

Second-line Treatment Option Identified for Small Cell Lung Cancer

06/23/2016

JCP Editors

A regimen containing cisplatin, etoposide, and irinotecan may be clinically beneficial as a second-line treatment for certain patients with small cell lung cancer, according to a clinical trial conducted in...

A...

06/23/2016

Journal of Clinical Pathways